Standard health insurance in Europe and North America does not cover experimental stem-cell therapies for muscular dystrophy. Most insurers classify these treatments as investigational and decline reimbursement. Private out-of-pocket payment is required at dedicated clinics, typically €4,000–8,000 per cycle. Clinical-trial participation occasionally offers free or subsidised access to active drug. Some rare-disease foundations or research charities may provide partial financial assistance for qualifying patients enrolled in legitimate trials. Patients should contact their insurer and disease advocacy groups to explore funding options before committing to private treatment.
Muscular dystrophy treatment costs typically range €4,000–7,500 per cycle, reflecting the need for multiple infusions and specialist neuromuscular assessment. Placental MSC sourcing and expansion for systemic administration incurs higher manufacturing expense than single-injection protocols. Disease severity and muscle group involvement influence whether local or systemic delivery is elected, affecting total cost. Many programmes require baseline and follow-up neuroimaging and strength testing, adding to overall expenses. European centres generally charge at the lower end of the range for research-protocol participation, whilst private clinics may exceed €8,000 per session.
Am I a candidate? → · Muscular Dystrophy: full overview → · Muscular Dystrophy cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment